Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 71

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part II, Item 3
Chunk 71
---
Item 3.    Defaults Upon Senior Securities

None.

Item 4.    Mine Safety Disclosures

None.

Item 5.    Other Information

(a)     None.

(b)    None.

(c)    Insider Trading Arrangements and Policies.

The table below lists the insider trading arrangements adopted or terminated during the first quarter of 2025:

35

Table of Contents

Name and Title of Director or OfficerRule 10b5-1 Trading Arrangement(1)Trading Arrangement Adopted or TerminatedDate of Adoption or TerminationDuration of Trading ArrangementAggregate Number of Securities to be Purchased Pursuant to Trading ArrangementAggregate Number of Securities to be Sold Pursuant to Trading ArrangementCharles NewhallYesAdopted March 3, 20253/3/202731,00031,000____________________________________(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).(2)This trading arrangement covers the exercise and sale of stock options, with a portion of such sales limited to an amount reasonably estimated such that the net proceeds from the sale are sufficient to cover the exercise cost and taxes associated with the exercise of the stock options.

Item 6.    Exhibits

The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q:ExhibitNumberDescription31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a).31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a).32.1Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline XBRL: (i) Cover Page, (ii) Condensed Consolidated Statements of Earnings (Loss), (iii) Condensed Consolidated Statements of Comprehensive Earnings (Loss), (iv) Condensed Consolidated Balance Sheets, (v) Condensed Consolidated Statements of Changes in Stockholders' Equity, (vi)